Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP3A5 Guided vs Weight-based Tacrolimus Dosing in Kidney Transplant
NCT04825262Completed
- Sponsor
- Singapore General Hospital
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tacrolimus in kidney transplant rejection (2 arms), sponsored by Singapore General Hospital. Primary endpoints: Proportion of patients within the desired FK trough level at first steady state at 3 days and Proportion of patients within the desired FK trough level at 7 days. Started Feb 2021; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04825262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825262.